Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSE-279 + OSE2101
- Development stage
- Unknown
- Lead developer
- OSE Immunotherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
OSE-279 + OSE2101 is a combination immunotherapy currently being investigated for advanced solid tumors, lymphomas, and metastatic non-small cell lung cancer (NSCLC). OSE-279 is a PD-1 (programmed death-1) blocking monoclonal antibody that enhances the immune system's ability to recognize and attack tumor cells by inhibiting an immune checkpoint pathway. OSE2101 (brand name: TEDOPI) is a T cell epitope-based cancer vaccine designed to stimulate a targeted immune response against tumor-associated antigens, specifically expanding tumor-specific T lymphocytes in patients with the HLA-A2 haplotype. The combination aims to synergistically boost anti-tumor immunity. Both agents were developed by the French biotechnology company OSE Immunotherapeutics and are being tested in a multicenter, interventional phase 1/2 study, including dose-finding and efficacy evaluations for combination therapy in HLA-A2 positive metastatic NSCLC patients.
- Other names
- OSE-279OSE279OSE 279OSE2101OSE-2101OSE 2101TEDOPI
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)PDCD1 (Programmed cell death protein 1 receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on OSE-279 + OSE2101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSE-279 + OSE2101.